A Study of Prevalence of Non Alcoholic Fatty Liver in Type 2 Diabetes Mellitus Patients

Rohini, I; Aarthi, N

doi:10.21276/ijcmr.2019.6.12.48

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 Recent research reveals its association with an elevated risk of cardiovascular events. [4][5][6][7][8][9] Simultaneously, MASLD's integral role in the complex interplay of insulin resistance and the development of type 2 diabetes mellitus is gaining recognition. 10,11 Literature suggests a bidirectional causal relationship between MASLD and diabetes mellitus, emphasizing the potential influence of insulin resistance in MASLD progression.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Njei,

Al-Ajlouni,

Lemos

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly impacts global health, with a prevalence affecting roughly 25% of adults worldwide. GLP-1 receptor agonists (GLP-1RAs) offer potential therapeutic benefits beyond glycemic control, including improvement in hepatic steatosis, inflammation, and fibrosis. Objectives: This study aims to systematically review and meta-analyze randomized clinical trials to evaluate the efficacy and safety of GLP-1RAs in MASLD patients, focusing on hepatic outcomes, cardiovascular outcomes, anthropometric measurements, and mortality. Methods: Following PRISMA guidelines, a comprehensive database search was conducted to include RCTs assessing GLP-1RAs’ effects on MASLD. Quality assessment was conducted using the Revised Cochrane Risk of Bias tool. Our meta-analysis utilized a random-effects model, calculating standardized mean differences for continuous outcomes to determine the agents’ efficacy and safety. Additionally, funnel plots were generated to assess publication bias, ensuring the integrity of our meta-analytical findings. Results: The review included 27 trials, revealing GLP-1RAs significantly improved hepatic function markers (ALT, AST, GGT, and liver fat content) and cardiovascular risk factors (fasting blood sugar, HbA1c levels, lipid profiles). Additionally, GLP-1RAs were associated with significant reductions in body weight, BMI, subcutaneous fat, and waist circumference. Conclusion: GLP-1RAs demonstrate a promising therapeutic role in managing MASLD, offering benefits that extend to improving liver function, mitigating cardiovascular risk, and promoting weight loss. Further research is needed to confirm these findings and optimize GLP-1RAs’ usage in MASLD treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Njei,

Al-Ajlouni,

Lemos

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Njei,

Al-Ajlouni,

Lemos

et al. 2024

Cureus

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a major global health challenge. glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential therapeutic benefits for MASLD patients, including improvements in liver function, inflammation, and fibrosis. This study aims to systematically review and meta-analyze randomized controlled trials (RCTs) to evaluate the efficacy and safety of GLP-1RAs in MASLD patients, focusing on hepatic outcomes, cardiovascular outcomes, anthropometric measurements, and mortality. Following PRISMA guidelines, a comprehensive database search was conducted to include RCTs assessing GLP-1RAs' effects on MASLD. Quality assessment was conducted using the Revised Cochrane Risk of Bias tool. Our meta-analysis used a random-effects model, calculating standardized mean differences for continuous outcomes to determine the agents' efficacy and safety. Additionally, funnel plots were generated to assess publication bias, ensuring the integrity of our meta-analytical findings. The review included 27 trials, revealing GLP-1RAs significantly improved hepatic function markers (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, and liver fat content) and cardiovascular risk factors (fasting blood sugar, HbA1c levels, lipid profiles). Additionally, GLP-1RAs were associated with significant reductions in body weight, BMI, subcutaneous fat, and waist circumference. GLP-1RAs demonstrate a promising therapeutic role in managing MASLD, offering benefits that extend to improving liver function, mitigating cardiovascular risk, and promoting weight loss. Further research is needed to confirm these findings and optimize GLP-1RAs' usage in MASLD treatment.

show abstract

A Study of Prevalence of Non Alcoholic Fatty Liver in Type 2 Diabetes Mellitus Patients

Cited by 2 publications

References 10 publications

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About